| abstract |
It refers to a group of hydronopol derivatives that are agonists of human ORL1 receptors (nociceptin). It also refers to the preparation of these compounds, to pharmaceutical compositions containing as an active ingredient a pharmacologically active amount of at least one of these new hydronopol derivatives, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. It refers to compounds of general formula 1 where the symbols have the meanings given in the specification. |